Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Targeted sequencing in endocrine refractory breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 1030

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

Dr Bartlett speaks with ecancer at ASCO 2017 about targeted sequencing in endocrine refractory breast cancer using specimens from a clinical trial of around 4,500 cases.

He mentions the ability to integrate both point mutation data, gene expression and copy number variation, where it is possible to identify pathways which are associated with hormone refractory cancers. 

This may give the capability to stratify patients by these pathways for future therapeutic development.


Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation